Introduction
The large number of experimental approaches, culture conditions, qualitative and quantitative methods, and in vitro and in vivo models employed so far to assess immune regulatory properties of multipotent mesenchymal stromal cells (MSCs) has led to an excess of literature data that sometimes are poorly comparable, redundant, and even contradictory.
Thus, quite paradoxically, the risk is that pre-clinical literature data may become eventually weak and scarcely useful, in both researchers' and Regulatory Authorities' opinion, for supporting experimentally specific MSC-based clinical trials aimed at treating autoimmune and inflammatory diseases. However, some data in this field appear more solid and reproducible and may be generally accepted to suggest reproducible immunological assays to quantify the differences in immune modulatory properties of MSCs produced according to
Good Manufacturing Practice (GMP).
The MSC Committee of the International Society of Cell Therapy (ISCT) released a statement paper in 2005 that established the minimal criteria characterizing human MSCs (1), without focusing particularly on their immunological properties. In the 7 years following the publication of this statement paper, more than 10,000 manuscripts containing the term "mesenchymal stem cell" or "multi-potent mesenchymal stromal cell" in the title or abstract have been catalogued in PubMed, and many of them deal with immune regulation. To consolidate the scientific research in this field, the MSC Committee of the ISCT is publishing a working proposal paper aimed at stimulating the general discussion about the need of shared guidelines for the immunological characterization of MSCs for clinical use (Box 1).
MSCs as immune modulators and the assessment of regulatory properties
MSCs can be obtained from tissues that originate from distinct development programs and that contain distinct pools of endogenous progenitor cells. Therefore, the properties of tissuespecific MSCs should be carefully evaluated prior to their clinical employment. MSCs or MSC-like cells have been identified in bone marrow (2, 3) , adipose tissue (4), and many other tissues and organs (5) including lymphoid tissues (6, 7) . MSCs have been identified in vivo as peri-vascular cells expressing the STRO1, CD146 and 3G5 antigens (8) (9) (10) (11) . Despite a close relationship between these two cell types in terms of surface phenotype and qualitative in vitro assays (11, 12) , MSCs in general lack the contractility of pericytes and may show marked differences in gene expression (12) , as well as by using more rigorous in vivo assays (13) . In addition, some Authors have described a neuro-ectodermal origin of MSCs through either Sox1 + neuro-epithelial cells (14) or Nestin + precursors (15 It is now clear that MSCs of different tissue sources (6, 7, 18) , as well as their stromal progeny (19) , can interact with, influence and even profoundly affect the in vitro functions of most effector cells involved in innate or adaptive immunity (20) . These properties have been the subject of many excellent reviews (21, 22) . However, some differences have been described 
Resting versus primed MSCs: the role of MSC activation
In a resting state, MSC are at a default niche, displaying mostly bystander anti-apoptotic and immune homeostatic features biased toward suppression. These properties can be greatly MSCs can suppress immunoglobulin production by B cells (6, 40, 50) . Cytofluorimetric evaluation of CD38/CD138 upregulation and parallel downregulation of CD20 seems to be a good approach to study the differentiation of memory B cells to plasma cells. ELISA or ELISpot can be used to monitor whole or specific immunoglobulin secretion by MSCs (51). followed by further 24-48 hour incubation in growth medium (24) .
MSC immunophenotyping as part of the immune plasticity response
Only a few studies have investigated MSCs and neutrophil interactions (56, 57) .
Human neutrophils, usually obtained from peripheral blood of normal volunteers, can be isolated with standard density-gradient separation methods (56) or high-purification procedures by positively removing all contaminating cells expressing CD3, CD56, CD19, CD36, CD49d, and Gly-A (57). The potential advantage of the latter method is that cell preparation is devoid of cells that might release factors influencing MSC and neutrophil functions regardless of their reciprocal interaction (57); consequently, high-purification procedure would be preferable to obtain more reproducible results. In any case, neutrophils should be manipulated under endotoxin-free conditions to avoid activation before co-culture with MSCs (56, 57) . Different stimuli (e.g., lipopolysaccharide, poly(I:C), phorbol esters), ratios of neutrophils to MSCs (from 1,000:1 to 10:1, in direct contact or in Transwell ® conditions) and functional assays (e.g., CD16 and CD11b expression as surrogate markers of neutrophil viability and activation, respectively; ELISA for cytokine detection; superoxide anion release for respiratory burst quantification) may be used to assess the effects of MSC-neutrophil interactions (56, 57) . The choice of one kind of stimulus rather than others would depend on which cell type needs to be activated to assess a specific effect. Poly(I:C) addition leads only to MSC activation via TLR3, as this receptor is not expressed by PMN (57) , and consequently the observed phenomena do not depend on the simultaneous PMN activation.
By contrast, LPS and phorbol esters activate both PMN and MSCs and the subsequent observed phenomena depend on the effects induced on both cell types. 100:1 and 10:1 PMN:MSC ratios and direct contact determine to the most evident effects on PMN survival, CD16 and CD11b expression, cytokine production and respiratory burst; all these phenomena may be assessed for a complete characterization of MSC effects on PMN;
however, CD16 and CD11b expression could be used as surrogate markers of neutrophil viability and activation, respectively (56, 57) .
In summary, the use of purified responders (as opposed to unfractionated PBMCs) coupled with a more "physiologic" activation stimulus may be widely practicable and provide more generalizable guidance in examining the relative functional potency of MSCs and as a companion to clinical trials.
MSC cellular biochemistry
Activation of IDO and iNOS is a pivotal mechanism in lymphocyte inhibition with MSCs, but species-specific differences exist. For example, after inflammatory priming, human MSCs express extremely high levels of IDO and low levels of iNOS (23, 58) , which is opposite to 
